MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-01-2024
Bausch Health Companies EBITDA per Share 2011-2026 | BHC
Annual EBITDA per Share Bausch Health Companies
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.1 | 5.1 | 5.58 | 7.05 | 9.06 | 8.98 | 9.21 | 10.9 | 13.2 | 11.9 | 6.75 | 5.29 | 3.24 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.2 | 3.24 | 7.87 |
Quarterly EBITDA per Share Bausch Health Companies
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.64 | - | - | - | 1.36 | - | 3.53 | 2.37 | 1.77 | - | 4.9 | 1.5 | 0.51 | -0.01 | 5.22 | 2.63 | 2.06 | -3.05 | 5.43 | 3.75 | 2.33 | 0.07 | 6.8 | 3.77 | -4.26 | -0.92 | 5.93 | 4.33 | 2.53 | 0.43 | 3.71 | 4.44 | 2.31 | 0.49 | 3.41 | 2.84 | 2.9 | 1.85 | 3.31 | 2.27 | 2.26 | - | 0.16 | 1.49 | 1.5 | - | 0.87 | 1.01 | 0.9 | - | 0.88 | 0.79 | 0.66 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.8 | -4.26 | 2.06 |
EBITDA per Share of other stocks in the Drug manufacturers industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-0.32 | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
0.27 | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-0.86 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.17 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.16 | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
-0.89 | $ 0.97 | 2.36 % | $ 104 M |  Canada |
 |
Aurora Cannabis
ACB
|
-1.67 | $ 3.31 | 1.53 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
-0.11 | $ 0.63 | 16.11 % | $ 11 M |  China |
 |
Catalent
CTLT
|
-1.44 | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-10 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.42 | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-0.504 | $ 2.52 | 5.44 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
-1.4 | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-11.7 | $ 8.05 | -1.71 % | $ 412 M | USA |
 |
Endo International plc
ENDP
|
1.3 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.22 | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-10.3 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-0.67 | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
0.22 | $ 3.05 | 7.77 % | $ 42.9 M | USA |
 |
Harrow Health
HROW
|
0.87 | $ 34.0 | 2.16 % | $ 1.25 B | USA |
 |
Assertio Holdings
ASRT
|
1.32 | $ 14.0 | 4.71 % | $ 89.6 M | USA |
 |
OptiNose
OPTN
|
-0.2 | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
-0.39 | $ 4.68 | 0.86 % | $ 302 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
6.31 | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
0.12 | $ 22.65 | 2.44 % | $ 1.05 B | USA |
 |
OrganiGram Holdings
OGI
|
-0.36 | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
2.8 | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-1.72 | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
1.79 | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
0.01 | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
-1.13 | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-1.5 | $ 5.86 | -3.46 % | $ 231 M | USA |
 |
Rockwell Medical
RMTI
|
-0.22 | $ 1.02 | -2.86 % | $ 23.8 M | USA |
 |
Lannett Company
LCI
|
-3.52 | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
-71 | $ 1.36 | 0.74 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
-0.32 | $ 0.88 | -6.09 % | $ 43.9 M | USA |
 |
Solid Biosciences
SLDB
|
-2.03 | $ 7.14 | 1.56 % | $ 625 M | USA |
 |
Organogenesis Holdings
ORGO
|
0.09 | $ 2.47 | 3.65 % | $ 325 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-106 | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
-5.67 | $ 9.57 | 3.46 % | $ 1.33 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.88 | $ 2.55 | 4.94 % | $ 3.16 M | USA |
 |
Tilray
TLRY
|
-2.22 | $ 6.45 | 3.86 % | $ 3.99 B | Canada |
 |
Recro Pharma
REPH
|
0.05 | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
-0.73 | $ 2.31 | 3.12 % | $ 24.1 M | USA |
 |
Veru
VERU
|
-0.27 | $ 2.3 | 1.32 % | $ 310 M | USA |
 |
Viatris
VTRS
|
2.92 | $ 13.29 | 0.68 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
-0.66 | $ 0.76 | 11.88 % | $ 3.28 M | USA |
 |
Tricida
TCDA
|
-2.97 | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |